Juvenile animal studies in the development of pediatric medicines: Experience from European medicines and pediatric investigation plans

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 92, Issue 4, 2011, Pages 353-358

  Duarte, Dinah M ^a   Silva Lima, Beatriz ^b  

^a INFARMED)   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

European Union; Juvenile animal studies; Juvenile toxicology; Nonclinical juvenile animal testing; Nonclinical safety evaluation; Pediatric investigation plans; Pediatric medicines

Indexed keywords

ANTIEMETIC AGENT; ANTIRETROVIRUS AGENT; ANTITHYROID AGENT; ANTIVIRUS AGENT; HORMONE; PLANT MEDICINAL PRODUCT;

ADOLESCENT; ANIMAL CARE; ANIMAL EXPERIMENT; ARTICLE; DRUG LEGISLATION; DRUG SAFETY; EUROPE; HUMAN; JUVENILE; NONHUMAN; PEDIATRICS; PRIORITY JOURNAL;

ANIMALS; ANIMALS, LABORATORY; BIOMEDICAL RESEARCH; CHILD; DRUG DESIGN; DRUG EVALUATION; DRUGS, INVESTIGATIONAL; HUMANS; MODELS, ANIMAL; PEDIATRICS; RATS; TOXICITY TESTS;

ANIMALIA; RATTUS;

EID: 80051946981     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.20299     Document Type: Article

References (29)

1. Anderson T, Khan NK, Tassinari MS, Hurtt ME. 2009. Comparative juvenile safety testing of new therapeutic candidates: relevance of laboratory animal data to children. J Toxicol Sci 34:209-215.
2. ATC/DDD Index 2010-Anatomical Therapeutic and Chemical Classification System, WHO Collaborating Centre for Drug Statistics Methodology. Available at: Consulted Jan 2010.
3. Bailey GP, Mariën D. 2009. What have we learned from pre-clinical juvenile toxicity studies? Reprod Toxicol 28:226-229.
4. Beckman DA, Schneider M, Youreneff M, Tse FL. 2008. Juvenile toxicity assessment of d, l-methylphenidate in rats. Birth Defects Res B 83:48-67.
5. Cappon G, Bailey G, Buschmann J, et al. 2009. Juvenile animal toxicity study designs to support pediatric drug development. Birth Defects Res (B) 86:2463-2469.
6. Ceci A, Felisi M, Catapano M, et al. 2002. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products. Eur J Clin Pharmacol 58:495-500.
7. Ceci A, Felisi M, Baiardi P, et al. 2006. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years. Eur J Clin Pharmacol 62:947-952.
8. De Schaepdrijver L, Bailey GP. 2009. Preclinical juvenile toxicity assessments and study designs. In: Mulberg AE, Silber SA, Van Der Anker JN, editors. Pediatric drug development: concepts and application. Hoboken, NJ: John Wiley & Sons. p 181-199.
9. De Schaepdrijver L, Rouan MC, Raoof A, et al. 2008. Real life juvenile toxicity case studies: the good, the bad and the ugly. Reprod Toxicol 26:54-55.
10. Duarte D, Silva-Lima B. 2009a. Juvenile Animal Studies in the development of medicines: learning with the experience. 12th Annual European Society for Developmental Perinatal & Paediatric Pharmacology Congress; Chamonix.
11. Duarte D, Silva-Lima B. 2009b. On the need for juvenile animal studies in paediatric drug development: experience from paediatric investigation plans. Reprod Toxicol 28:126.
12. EC. 2006. Regulation (EC) No. 1901/2006 Official Journal of the European Union 378, 27.12.2006:1-19.
13. EC. 2010. The Community Register of medicinal products. European Commission. Available at: Consulted January 2010.
14. EMA. 2008a. Guideline on the need for non-clinical testing in juvenile animals on human pharmaceuticals for paediatric indications. Ref. EMEA/CHMP/SWP/169215/2008. Available at: Consulted January 2010.
15. EMA. 2008b. Press Release. 2008. Meeting highlights from the Paediatric Committee, October 15-17, 2008. Doc. Ref. EMEA/PDCO/552811/2008. Available at: Consulted February 2010.
16. EMA. 2009. EMA Press Release, Meeting highlights from the Paediatric Committee, December 09-11, 2009. Doc. Ref. EMA/PDCO/788549/2009. Available at: Consulted February 2010.
17. EMA. 2010a. EPARs for authorised medicinal products for human use. Available at: Consulted January 2010.
18. EMA. 2010b. Opinions and decisions on PIP applications. European Medicines Agency decisions on paediatric investigation plans (PIPs), including deferrals and waivers, and on modification of an agreed PIP. Available at: Consulted February 2010.
19. FDA. 2006. Guidance for industry: nonclinical safety evaluation of pediatric drug products. 2006. Available at: Consulted May 2010.
20. Hurtt ME, Daston G, Davis-Bruno K, et al. 2004. Juvenile animal studies: testing strategies and design. Birth Defects Res (B) 71:281-288.
21. ICH. 2000. M3(R1) maintenance of the ICH guideline on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. 2000. Available at Consulted January 2010.
22. Lindell-Osuagwu L, Korhonen M, JSaano S, et al. 2009. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 34:277-287.
23. Morales-Carpi C, Estañ L, Rubio E, et al. 2009. Drug utilization and off-label drug use among Spanish emergency room paediatric patients. Eur J Clin Pharmacol (02.11.2009 Online).
24. Ridings JE, Maguire SR, Burns AK. 2008. Nonclinical support of paediatric drug development. Reprod Toxicol 26:72-73.
25. Schirm E, Tobi H, de Jong-van den Berg LTW. 2002. Unlicensed and off label drug use by children in the community: cross sectional study. Br Med J 324:1312-1313.
26. Silva Lima B. 2003. Juvenile animals in safety testing: the European regulatory perspective. Reprod Toxicol 17:476-477.
27. Silva Lima B, Due Theilade-Thomsen M, Carleer J, et al. 2010. Juvenile animal studies for the development of paediatric medicines: a description and conclusions from a European medicines agency workshop on juvenile animal testing for nonclinical assessors. Birth Defects Res (B) 89:467-473.
28. 't Jong GW, van der Linden PD, Bakker EM, et al. 2002. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol 58:293-297.
29. US Environmental Protection Agency. US EPA. 2002. A review of the reference dose and reference concentration processes. Risk Assessment Forum, Washington, DC, EPA/630/P-02/002F.